. . "149121"^^ . . "Vaksin malaria"@in . "Il vaccino anti-malaria, chiamato anche vaccino contro la malaria o vaccino antimalarico, \u00E8 un vaccino che viene utilizzato per prevenire la malaria. L'unico vaccino approvato dall'OMS, a partire dall'ottobre 2021, \u00E8 il RTS,S conosciuto con il nome commerciale di Mosquirix. Un altro vaccino ancora in fase di sviluppo \u00E8 il , che ha registrato un tasso di efficacia del 77%, mostrando negli studi un livello di anticorpi significativamente pi\u00F9 alto rispetto al vaccino RTS,S. Questo \u00E8 il primo vaccino che ha registrato un'efficacia di almeno il 75%. Nel 2022 la OMS ha interrotto la sperimentazione sul Vaccino antimalarico, che era in corso in Kenya, Ghana e Malawi, i risultati non erano soddisfacenti ed i costi troppo elevati. Per proseguire la ricerca occorreva che l'efficacia fosse superiore al 50%, invece era vicina vicina al 30%."@it . "Vacc\u00ED contra la mal\u00E0ria"@ca . "Malaria vaccine"@en . "57685"^^ . . "vaccine"@en . . . . . "Vaccino anti-malaria"@it . . . "A malaria vaccine is a vaccine that is used to prevent malaria. The only approved use of a vaccine outside the EU, as of 2022, is RTS,S, known by the brand name Mosquirix. In October 2021, the WHO for the first time recommended the large-scale use of a malaria vaccine for children living in areas with moderate-to-high malaria transmission. Four injections are required for full protection. Research continues with other malaria vaccines. The most effective malaria vaccine is R21/Matrix-M, with a 77% efficacy rate shown in initial trials and significantly higher antibody levels than with the RTS,S vaccine. It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy."@en . "\u0644\u0642\u0627\u062D \u0627\u0644\u0645\u0644\u0627\u0631\u064A\u0627 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Malaria vaccine)\u200F\u0647\u0648 \u0644\u0642\u0627\u062D \u064A\u0633\u062A\u062E\u062F\u0645 \u0644\u0645\u0646\u0639 \u0627\u0644\u0625\u0635\u0627\u0628\u0629 \u0628\u0627\u0644\u0645\u0644\u0627\u0631\u064A\u0627 . \u0627\u0644\u0644\u0642\u0627\u062D \u0627\u0644\u0648\u062D\u064A\u062F \u0627\u0644\u0645\u0639\u062A\u0645\u062F \u0627\u0639\u062A\u0628\u0627\u0631\u064B\u0627 \u0645\u0646 2021 \u0647\u0648 RTS\u060C S. \u064A\u062A\u0637\u0644\u0628 \u0627\u0644\u0623\u0645\u0631 \u0623\u0631\u0628\u0639 \u062D\u0642\u0646\u060C \u0648\u0644\u0647 \u0641\u0639\u0627\u0644\u064A\u0629 \u0645\u0646\u062E\u0641\u0636\u0629 \u0646\u0633\u0628\u064A\u064B\u0627 (26-50\u066A). \u0648\u0628\u0633\u0628\u0628 \u0647\u0630\u0647 \u0627\u0644\u0641\u0639\u0627\u0644\u064A\u0629 \u0627\u0644\u0645\u0646\u062E\u0641\u0636\u0629\u060C \u0644\u0627 \u062A\u0648\u0635\u064A \u0645\u0646\u0638\u0645\u0629 \u0627\u0644\u0635\u062D\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064A\u0629 \u0628\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0644\u0642\u0627\u062D RTS\u060C S \u0628\u064A\u0646 \u0627\u0644\u0623\u0637\u0641\u0627\u0644 \u0627\u0644\u0630\u064A\u0646 \u062A\u062A\u0631\u0627\u0648\u062D \u0623\u0639\u0645\u0627\u0631\u0647\u0645 \u0628\u064A\u0646 6 \u0648 12 \u0623\u0633\u0628\u0648\u0639\u064B\u0627.. \u0628\u062F\u0623\u062A \u062F\u0631\u0627\u0633\u0629 \u0627\u0644\u0644\u0642\u0627\u062D \u0648\u062A\u062C\u0631\u0628\u062A\u0647 \u0628\u0634\u0643\u0644 \u0623\u0643\u0628\u0631 \u0641\u064A \u0623\u0641\u0631\u064A\u0642\u064A\u0627 \u0641\u064A \u0639\u0627\u0645 2018. \u064A\u0633\u062A\u0645\u0631 \u0627\u0644\u0628\u062D\u062B \u0641\u064A \u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0645\u0624\u062A\u0644\u0641\u0629 \u0645\u0646 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646 \u0627\u0644\u062D\u064A \u0648\u0627\u0644\u0645\u0648\u0647\u0646."@ar . . . . . . . . . . . . . . . . . "Rx-only"@en . . . . "10280304"^^ . . "Mosquirix"@en . "Mosquirix"@en . "Malariaimpfstoff"@de . . . . . . . . . "1124253449"^^ . . . . "149121-47-1" . . . . . . . . . . . . "None"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "\u0644\u0642\u0627\u062D \u0627\u0644\u0645\u0644\u0627\u0631\u064A\u0627"@ar . . "Ein Malariaimpfstoff ist ein Impfstoff gegen Plasmodien, die Erreger der Malaria. Die Entwicklung von Malariaimpfstoffen stellt in der Forschung eine besondere Herausforderung dar, da Malariaerkrankungen in Menschen keine vollst\u00E4ndige Immunit\u00E4t gegen weitere Erkrankungen hervorrufen. Die Strategie, Menschen mit abgeschw\u00E4chten oder get\u00F6teten Erregern zu injizieren um eine Immunreaktion auszul\u00F6sen, ist somit deutlich weniger praktikabel, als es bei etablierten Impfungen wie zum Beispiel der Grippe oder Polio der Fall ist. Aktuell gibt es weltweit nur einen einzigen im Zulassungsverfahren befindlichen Malariaimpfstoff, genannt RTS,S. Die Effektivit\u00E4t des Impfstoffes ist zwar vergleichsweise niedrig, stellt aber dennoch einen wesentlichen Fortschritt dar und wurde deshalb 2015 von der Weltgesundheitsorganisation (WHO) f\u00FCr ein vorl\u00E4ufiges Impfprogramm empfohlen, welches 2019 in Ghana, Kenia, und Malawi begann. Basierend auf den Pilotversuchen empfahl die WHO im Oktober 2021 die breite Anwendung des Vakzins RTS,S f\u00FCr den Kampf gegen Malaria."@de . "Una vacuna contra la mal\u00E0ria \u00E9s una vacuna que s'utilitza per prevenir la mal\u00E0ria. L'\u00FAnica vacuna aprovada a partir del 2021 \u00E9s RTS,S, coneguda amb la marca Mosquirix. Requereix quatre injeccions. La investigaci\u00F3 continua amb altres vacunes contra la mal\u00E0ria. La vacuna contra la mal\u00E0ria que sembla m\u00E9s efica\u00E7 \u00E9s la R21/Matrix-M, amb una taxa d'efic\u00E0cia del 77% mostrada en els assaigs inicials, i amb nivells d\u2019anticossos significativament m\u00E9s alts que amb la vacuna RTS,S. \u00C9s la primera vacuna que compleix l'objectiu de l'Organitzaci\u00F3 Mundial de la Salut (OMS) d'una vacuna contra la mal\u00E0ria amb almenys un 75% d'efic\u00E0cia."@ca . . . . . . . . . . . . . . . . . . . "February 2018"@en . . . . . . . . . "Long history of failed attempts; current material is one-sided and mainly recent."@en . . . . . . . . . "\u0644\u0642\u0627\u062D \u0627\u0644\u0645\u0644\u0627\u0631\u064A\u0627 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Malaria vaccine)\u200F\u0647\u0648 \u0644\u0642\u0627\u062D \u064A\u0633\u062A\u062E\u062F\u0645 \u0644\u0645\u0646\u0639 \u0627\u0644\u0625\u0635\u0627\u0628\u0629 \u0628\u0627\u0644\u0645\u0644\u0627\u0631\u064A\u0627 . \u0627\u0644\u0644\u0642\u0627\u062D \u0627\u0644\u0648\u062D\u064A\u062F \u0627\u0644\u0645\u0639\u062A\u0645\u062F \u0627\u0639\u062A\u0628\u0627\u0631\u064B\u0627 \u0645\u0646 2021 \u0647\u0648 RTS\u060C S. \u064A\u062A\u0637\u0644\u0628 \u0627\u0644\u0623\u0645\u0631 \u0623\u0631\u0628\u0639 \u062D\u0642\u0646\u060C \u0648\u0644\u0647 \u0641\u0639\u0627\u0644\u064A\u0629 \u0645\u0646\u062E\u0641\u0636\u0629 \u0646\u0633\u0628\u064A\u064B\u0627 (26-50\u066A). \u0648\u0628\u0633\u0628\u0628 \u0647\u0630\u0647 \u0627\u0644\u0641\u0639\u0627\u0644\u064A\u0629 \u0627\u0644\u0645\u0646\u062E\u0641\u0636\u0629\u060C \u0644\u0627 \u062A\u0648\u0635\u064A \u0645\u0646\u0638\u0645\u0629 \u0627\u0644\u0635\u062D\u0629 \u0627\u0644\u0639\u0627\u0644\u0645\u064A\u0629 \u0628\u0627\u0633\u062A\u062E\u062F\u0627\u0645 \u0644\u0642\u0627\u062D RTS\u060C S \u0628\u064A\u0646 \u0627\u0644\u0623\u0637\u0641\u0627\u0644 \u0627\u0644\u0630\u064A\u0646 \u062A\u062A\u0631\u0627\u0648\u062D \u0623\u0639\u0645\u0627\u0631\u0647\u0645 \u0628\u064A\u0646 6 \u0648 12 \u0623\u0633\u0628\u0648\u0639\u064B\u0627.. \u0628\u062F\u0623\u062A \u062F\u0631\u0627\u0633\u0629 \u0627\u0644\u0644\u0642\u0627\u062D \u0648\u062A\u062C\u0631\u0628\u062A\u0647 \u0628\u0634\u0643\u0644 \u0623\u0643\u0628\u0631 \u0641\u064A \u0623\u0641\u0631\u064A\u0642\u064A\u0627 \u0641\u064A \u0639\u0627\u0645 2018. \u064A\u0633\u062A\u0645\u0631 \u0627\u0644\u0628\u062D\u062B \u0641\u064A \u0627\u0644\u0644\u0642\u0627\u062D\u0627\u062A \u0627\u0644\u0645\u0624\u062A\u0644\u0641\u0629 \u0645\u0646 \u0627\u0644\u0628\u0631\u0648\u062A\u064A\u0646 \u0627\u0644\u062D\u064A \u0648\u0627\u0644\u0645\u0648\u0647\u0646."@ar . . . . . . "none"@en . . . . . . . "Ein Malariaimpfstoff ist ein Impfstoff gegen Plasmodien, die Erreger der Malaria. Die Entwicklung von Malariaimpfstoffen stellt in der Forschung eine besondere Herausforderung dar, da Malariaerkrankungen in Menschen keine vollst\u00E4ndige Immunit\u00E4t gegen weitere Erkrankungen hervorrufen. Die Strategie, Menschen mit abgeschw\u00E4chten oder get\u00F6teten Erregern zu injizieren um eine Immunreaktion auszul\u00F6sen, ist somit deutlich weniger praktikabel, als es bei etablierten Impfungen wie zum Beispiel der Grippe oder Polio der Fall ist."@de . "Una vacuna contra la mal\u00E0ria \u00E9s una vacuna que s'utilitza per prevenir la mal\u00E0ria. L'\u00FAnica vacuna aprovada a partir del 2021 \u00E9s RTS,S, coneguda amb la marca Mosquirix. Requereix quatre injeccions. La investigaci\u00F3 continua amb altres vacunes contra la mal\u00E0ria. La vacuna contra la mal\u00E0ria que sembla m\u00E9s efica\u00E7 \u00E9s la R21/Matrix-M, amb una taxa d'efic\u00E0cia del 77% mostrada en els assaigs inicials, i amb nivells d\u2019anticossos significativament m\u00E9s alts que amb la vacuna RTS,S. \u00C9s la primera vacuna que compleix l'objectiu de l'Organitzaci\u00F3 Mundial de la Salut (OMS) d'una vacuna contra la mal\u00E0ria amb almenys un 75% d'efic\u00E0cia."@ca . . . . . . "Vaksin malaria adalah vaksin yang digunakan untuk mencegah malaria. Satu-satunya vaksin malaria yang mendapatkan persetujuan adalah RTS,S, yang dikenal dengan nama dagang Mosquirix. Pada Oktober 2021, vaksin tersebut disetujui oleh Organisasi Kesehatan Dunia (WHO) untuk \"digunakan secara luas\" pada anak-anak sehingga menjadikannya kandidat vaksin malaria pertama yang menerima rekomendasi ini. Vaksin ini membutuhkan empat suntikan dan memiliki yang relatif rendah. Penelitian untuk membuat vaksin malaria lainnya terus berlanjut. Vaksin malaria paling efektif yang ditemukan sejauh ini adalah R21/Matrix-M, dengan tingkat efikasi sebesar 77% pada uji coba awal dan menghasikan tingkat antibodi yang jauh lebih tinggi dibandingkan dengan vaksin RTS,S. Vaksin R21/Matrix-M adalah vaksin pertama yang memenuhi target WHO tentang vaksin malaria, yaitu memiliki efikasi setidaknya sebesar 75%."@in . . . . . . . . . "A vacina contra a mal\u00E1ria \u00E9 uma vacina destinada a prevenir a mal\u00E1ria, doen\u00E7a parasit\u00F3ria transmitida pelas f\u00EAmeas infectadas do mosquito Anopheles. A \u00FAnica vacina aprovada a partir de 2015 \u00E9 a RTS,S, conhecida pelo nome comercial Mosquirix. Requer quatro inje\u00E7\u00F5es e tem uma relativamente baixa. Devido a essa baixa efic\u00E1cia, a Organiza\u00E7\u00E3o Mundial da Sa\u00FAde (OMS) n\u00E3o recomenda o uso rotineiro da vacina RTS,S em beb\u00EAs entre 6 e 12 semanas de idade. Um programa de implementa\u00E7\u00E3o liderado pela OMS est\u00E1 testando a vacina em tr\u00EAs pa\u00EDses com alto \u00EDndice de mal\u00E1ria na \u00C1frica em 2019. A primeira fase do projeto, coberta por doa\u00E7\u00F5es da Unitaid, Gavi e do Fundo Global, est\u00E1 planejada para estabelecer a viabilidade, o impacto e a seguran\u00E7a do RTS,S, quando usado como parte de um programa de imuniza\u00E7\u00E3o de rotina. A pesquisa continua com prote\u00EDnas recombinantes e vacinas atenuadas para todo o organismo."@pt . . . . "Screened cup of malaria-infected mosquitoes which will infect a volunteer in a clinical trial"@en . . . . "Il vaccino anti-malaria, chiamato anche vaccino contro la malaria o vaccino antimalarico, \u00E8 un vaccino che viene utilizzato per prevenire la malaria. L'unico vaccino approvato dall'OMS, a partire dall'ottobre 2021, \u00E8 il RTS,S conosciuto con il nome commerciale di Mosquirix. Un altro vaccino ancora in fase di sviluppo \u00E8 il , che ha registrato un tasso di efficacia del 77%, mostrando negli studi un livello di anticorpi significativamente pi\u00F9 alto rispetto al vaccino RTS,S. Questo \u00E8 il primo vaccino che ha registrato un'efficacia di almeno il 75%."@it . . . . . "A vacina contra a mal\u00E1ria \u00E9 uma vacina destinada a prevenir a mal\u00E1ria, doen\u00E7a parasit\u00F3ria transmitida pelas f\u00EAmeas infectadas do mosquito Anopheles. A \u00FAnica vacina aprovada a partir de 2015 \u00E9 a RTS,S, conhecida pelo nome comercial Mosquirix. Requer quatro inje\u00E7\u00F5es e tem uma relativamente baixa. Devido a essa baixa efic\u00E1cia, a Organiza\u00E7\u00E3o Mundial da Sa\u00FAde (OMS) n\u00E3o recomenda o uso rotineiro da vacina RTS,S em beb\u00EAs entre 6 e 12 semanas de idade."@pt . "Vaksin malaria adalah vaksin yang digunakan untuk mencegah malaria. Satu-satunya vaksin malaria yang mendapatkan persetujuan adalah RTS,S, yang dikenal dengan nama dagang Mosquirix. Pada Oktober 2021, vaksin tersebut disetujui oleh Organisasi Kesehatan Dunia (WHO) untuk \"digunakan secara luas\" pada anak-anak sehingga menjadikannya kandidat vaksin malaria pertama yang menerima rekomendasi ini. Vaksin ini membutuhkan empat suntikan dan memiliki yang relatif rendah."@in . . . . . . . . . "Vacina contra a mal\u00E1ria"@pt . "protein"@en . . . . "A malaria vaccine is a vaccine that is used to prevent malaria. The only approved use of a vaccine outside the EU, as of 2022, is RTS,S, known by the brand name Mosquirix. In October 2021, the WHO for the first time recommended the large-scale use of a malaria vaccine for children living in areas with moderate-to-high malaria transmission. Four injections are required for full protection."@en . . . . . .